2 new bone lesions on high-dose garetosmab versus 19 on placebo in FOP Phase 3
Adults on garetosmab developed 2 new bone lesions in the high-dose arm and 1 in the low-dose arm over 56 weeks, against 19 on placebo, in Regeneron's OPTIMA Phase 3. The results give arm-level lesion, flare-up and safety figures for both doses of the drug approved as PASATRU.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
The 63 adults with fibrodysplasia ossificans progressiva (FOP) randomized in the OPTIMA trial accumulated 1 new heterotopic ossification (HO) lesion in the low-dose garetosmab arm and 2 in the high-dose arm over 56 weeks, against 19 in the placebo arm, the study record shows. Adults with FOP now have arm-level lesion counts, flare-up rates and safety results for two intravenous doses against placebo across a 56-week double-blind period, from a trial Regeneron Pharmaceuticals sponsored.
Why it matters
PASATRU (garetosmab) is indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, according to its prescribing information (DailyMed: PASATRU label), a label version published Aug 24, 2026. That label also states that the safety and effectiveness of PASATRU have not been established in pediatric patients (DailyMed: PASATRU label). The study's stated aim was to see how safe and effective the study drug is in patients with FOP, its record summary states. The record also cites a Lancet publication of the trial's efficacy and safety analysis, dated 2026 Sep 28.
New HO lesions at Week 56
Results were first posted 2026-11-17. Primary data collection was completed 2025-07-17. A total of 67 participants were screened, of whom 63 met eligibility criteria and were randomized into one of 3 arms. The primary outcome was the cumulative number of new HO lesions across all participants, with new HO lesions defined as HO lesions detectable by computed tomography (CT) that developed after baseline:
- Cumulative new HO lesions at Week 56: 1 in the low-dose arm (19 participants), 2 in the high-dose arm (23 participants) and 19 in the placebo arm (21 participants)
- Negative binomial regression estimates versus placebo: 0.06 for low dose (95% confidence interval 0.00 to 0.73; p=0.0274) and 0.10 for high dose (95% confidence interval 0.01 to 0.76; p=0.0260)
- Participants with at least one new HO lesion at Week 56: 1 of 19 on low dose, 2 of 23 on high dose and 5 of 21 on placebo
- Mean total volume of new HO lesions at Week 56: 0.01 cubic centimeters (standard deviation 0.04) on low dose, 0.02 cubic centimeters (standard deviation 0.06) on high dose and 10.97 cubic centimeters (standard deviation 37.37) on placebo
Flare-ups
Clinician-assessed flare-ups, characterized as episodic, painful inflammatory soft tissue swelling and assessed by the investigator according to medical judgment, numbered 9 across the high-dose arm through Week 56, against 53 in the low-dose arm and 66 in the placebo arm; at Week 28 the counts were 5, 38 and 42 in the same arms. The percentage of participants with a clinician-assessed flare-up through Week 56 was 21.7% on high dose, 42.1% on low dose and 71.4% on placebo. Participant-reported flare-ups, defined as two or more of pain, swelling, joint stiffness, or decrease in movement and self-recorded daily, affected 47.8% of the high-dose arm, 57.9% of the low-dose arm and 61.9% of the placebo arm through Week 56.
Safety
Four of 23 high-dose participants had a treatment-emergent adverse event of special interest; the record lists 4 as treatment-related and 1 as serious. One of 21 placebo participants had such an event, also listed as treatment-related, and 0 of 19 low-dose participants did. The record reports 0 events of special interest in the categories of study treatment discontinuation and death. Serious adverse events were reported in 1 of 19 low-dose participants, 2 of 23 high-dose participants and 2 of 21 placebo participants, with no deaths in any arm. Other adverse events, excluding serious ones, were reported in 18 of 19 low-dose participants, 22 of 23 high-dose participants and 21 of 21 placebo participants. The events of special interest were epididymitis, orchitis, hydrocele, scrotum pain and/or scrotum swelling; moderate-to-severe episodes of spontaneous non-traumatic bleeding; moderate epistaxis; severe epistaxis; and skin infection or abscess that requires referral to a specialist for treatment.
The trial and its participants
OPTIMA was a Phase 3, randomized, parallel trial with masking of participant, care provider, investigator and outcomes assessor. Garetosmab was administered intravenously every 4 weeks (Q4W); the safety tables label the arms Low Dose Garetosmab 3 mg and High Dose Garetosmab 10 mg. All 19 low-dose and 23 high-dose participants completed the 56-week double-blind treatment period, as did 20 of 21 placebo participants; the 1 placebo participant who did not complete it discontinued because of an adverse event.
Participants were adults with a clinical diagnosis of FOP, based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive HO, and confirmation of the diagnosis with documentation of a Type I activin A receptor (ACVR1) FOP causing mutation. The record lists FOP disease activity within 1 year of screening as a requirement, and the trial excluded participants with a CAJIS score above 19 at screening. Mean age was 26.6 years (standard deviation 6.8); 38 participants were female and 25 male.
What remains uncertain
Five outcomes measured at Week 84 in participants on extended treatment, covering the number and percentage of new HO lesions, total lesion volume and clinician-assessed flare-ups, have no results posted in the record (the study record shows).
Sources
- ClinicalTrials.gov: A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP), results first posted 2026-11-17
- DailyMed: PASATRU (GARETOSMAB-GRTS) INJECTION, SOLUTION, CONCENTRATE, label version published Aug 24, 2026